End-stage ankle osteoarthritis causes severe pain and disability. There are no randomized trials comparing the 2 main surgical treatments: total ankle replacement (TAR) and ankle fusion (AF).
To determine which treatment is superior in terms of clinical scores and adverse events.
Design: A multicenter, parallel-group, open-label randomized trial. (ISRCTN registry number: 60672307).
Setting: 17 National Health Service trusts across the United Kingdom.
Patients: Patients with end-stage ankle osteoarthritis, aged 50 to 85 years, and suitable for either procedure.
Intervention: Patients were randomly assigned to TAR or AF surgical treatment.
Measurements: The primary outcome was change in Manchester-Oxford Foot Questionnaire walking/standing (MOXFQ-W/S) domain scores between baseline and 52 weeks after surgery. No blinding was possible.
Limitations: Only 52-week data; pragmatic design creates heterogeneity of implants and surgical techniques.
Both TAR and AF improve MOXFQ-W/S and had similar clinical scores and number of harms. Total ankle replacement had greater wound healing complications and nerve injuries, whereas AF had greater thromboembolism and nonunion, with a symptomatic nonunion rate of 7%.
Copyright remains with the authors and publisher.
End-stage ankle osteoarthritis causes severe pain and disability. There are no randomized trials comparing the 2 main surgical treatments: total ankle replacement (TAR) and ankle fusion (AF).
To determine which treatment is superior in terms of clinical scores and adverse events.
Design: A multicenter, parallel-group, open-label randomized trial. (ISRCTN registry number: 60672307).
Setting: 17 National Health Service trusts across the United Kingdom.
Patients: Patients with end-stage ankle osteoarthritis, aged 50 to 85 years, and suitable for either procedure.
Intervention: Patients were randomly assigned to TAR or AF surgical treatment.
Measurements: The primary outcome was change in Manchester-Oxford Foot Questionnaire walking/standing (MOXFQ-W/S) domain scores between baseline and 52 weeks after surgery. No blinding was possible.
Limitations: Only 52-week data; pragmatic design creates heterogeneity of implants and surgical techniques.
Both TAR and AF improve MOXFQ-W/S and had similar clinical scores and number of harms. Total ankle replacement had greater wound healing complications and nerve injuries, whereas AF had greater thromboembolism and nonunion, with a symptomatic nonunion rate of 7%.
Copyright remains with the authors and publisher.